Skip to content
Est. 1998 proudly celebrating our 27th year of championing American business
American Origin Unverified This profile is unclaimed and has not been independently reviewed. Claim & get verified

Decoy Therapeutics Inc.

  • HOUSTON, Texas
  • Public · NASDAQ: DCOY
  • 11 employees
$3.5MMarket cap
$0Revenue · FY2022
-$12.5MNet income
11Employees
DCOYNASDAQ
2015IPO

About Decoy Therapeutics Inc.

Decoy Therapeutics Inc is a pre-clinical stage biotechnology company focused on advancing its pipeline of peptide conjugate therapeutics engineered through its proprietary IMP3ACT platform. The IMP3ACT platform represents a paradigm shift in peptide conjugate drug discovery and manufacturing, leveraging machine learning (ML) and artificial intelligence (AI" tools alongside high-speed synthesis techniques to rapidly engineer, optimize and manufacture peptide conjugates that target serious unmet medical needs. The company manages its business in one operating segment, focused on the discovery and development therapeutics for patients with high, unmet medical needs. Its pipeline programs include: Pan-Coronavirus; and Tripledemic.

This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.

Reported figures

Financial summary

Revenue FY2022
$0
Net income
-$12.5M
Total assets
$11.1M
Market cap
$3.5M

Source: SEC EDGAR · updated Jun 7, 2026

NASDAQ: DCOY

15-minute delayed · data by Polygon.io

Market cap
$3.5M
Open
Day range
Prev close
Volume
IPO date
Jan 29, 2015

Market data by Polygon.io · prices are 15-minute delayed

No reviews yet. Be the first to review Decoy Therapeutics Inc..

Write a review
Explore

Similar companies

Browse all →